Completed Clinical Trials

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

By April 24, 2017No Comments


Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer

Estimated Enrollment: 27

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: HREC/13/CRGH/199

Study First Received: January 5, 2015

Last Updated: April 5, 2017

Estimated Primary Completion Date: January 4, 2017


Primary Outcome Measures:

There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.|to evaluate the effect of multiple dosing of TargomiRs|to detect early signs of efficacy|QOL assessment|ECOG PS change|Pulmonary function change

Sponsors and Collaborators:

Asbestos Diseases Research Foundation|EnGeneIC Limited

Website Link:

Leave a Reply

Call Now ButtonCall Now